OSE Immunotherapeutics Reports Phase 2 Tedopi Combo Survival Data
In metastatic NSCLC, one-year overall survival was 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab, versus 29% with docetaxel. Median overall survival was 11.9 and 11.3 months, respectively, versus 6.4 months for control.
OSE Immunotherapeutics reported final Phase 2 Combi-TED data: 1-yr OS was 47% for Tedopi+docetaxel and 46% for Tedopi+nivolumab vs 29% for docetaxel in metastatic NSCLC; median OS 11.9 and 11.3 months vs 6.4 months for control.Material DetailsContext by AI AnalystThis is mid-stage confirmation addi…